Will the pill help defeat the coronavirus?
Abstract
N/A
References
Lipman M, Chambers RC, Singer M, et al. (2020). SARS-CoV-2 pandemic: clinical picture of COVID-19 and implications for research. Thorax 2020; 75:614-616.
J. H. Stone, M. J. Frigault, N. J. Serling-Boyd et al. (2020). Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. NEJM, October 21, 2020, DOI: 10.1056/NEJMoa2028836
M. Ackermann, S. E. Verleden, M. Kuehnel at al. (2020). Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. May 21, 2020. DOI: 10.1056/NEJMoa2015432
Martines RB, Ritter JM, Matkovic E et al; COVID-19 Pathology Working Group (2020). Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United States. Emerg Infect Dis. 2020 Sep;26(9):2005-2015. doi: 10.3201/eid2609.202095. Epub 2020 May 21. PMID: 32437316; PMCID: PMC7454055.
C.N.Englisch, T.Tschernig,F,Flockerzi et al. (2020). Lesions in the lungs of fatal corona virus disease Covid-19.AnnalsofAnatomy-AnatomischerAnzeiger,2020. https://doi.org/10.1016/j.aanat.2020.151657
J. H. Beigel, K. M. Tomashek, L. E. Dodd et al. (2020). Remdesivir for the Treatment of Covid-19 — Final Report. November 5, 2020, N Engl J Med 2020; 383:1813-1826. DOI: 10.1056/NEJMoa2007764
V. A. Simonovich, L. D. Burgos Pratx, P. Scibona et al. (2020). A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. November 24, 2020. DOI: 10.1056/NEJMoa2031304
O. Mitjà, M. Corbacho-Monné, M. Ubals et al. (2020). A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. November 24, 2020. DOI: 10.1056/NEJMoa2021801
WHO Solidarity Trial Consortium (2020). Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. December 2, 2020. DOI: 10.1056/NEJMoa2023184
E. Huang, S. C. Jordan (2020). Tocilizumab for Covid-19 — the Ongoing Search for Effective Therapies. December 10, 2020. N Engl J Med 2020; 383:2387-2388. DOI: 10.1056/NEJMe2032071
A. Liapikou, E. Rosales-Mayor, A. Torres (2014). The management of severe community acquired pneumonia in the ICU. June 2014, Expert Review of Respiratory Medicine 8(3):293-303.DOI: 10.1586/17476348.2014.896202
J. W. Kim, , J.J. Kim, H. J. Yang at al.(2015). The Prognostic Factors of Pneumonia with Septic Shock in Patients Presenting to the Emergency Department. Korean Journal of Critical Care Medicine 2015; 30(4): 258-264
P. Jason ,N. C. Dean, Q. Guo et al. (2016). Severe community-acquired pneumonia: timely management measures in the first 24 hours. Critical Care,2016,20:237
A. Vidal, L. Santos (2017). Comorbidities impact on the prognosis of severe acute community-acquired pneumonia. Porto Biomedical Journal, Vol. 2. Num. 6. November - December 2017, pages 247-346
A.Ceccato, A. Torres (2018). Sepsis and community-acquired pneumonia. Ann Res Hosp 2018; 2:7
https://en.wikipedia.org/wiki/Severe_acute_respiratory_syndrome
Rawson TM, Moore LSP, Zhu N, et al. (2020). Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing [published online ahead of print, 2020 May 2]. Clin Infect Dis. 2020;ciaa530. doi:10.1093/cid/ciaa530
Beović, M. Doušak, J. Ferreira-Coimbra et al. (2020). Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey. Journal of Antimicrobial Chemotherapy, dkaa326, https://doi.org/10.1093/jac/dkaa326
Kim D, Quinn J, Pinsky B et al. (2020). Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA 2020; 323: 2085–6.
Ocampo-Torres Moisés., et al. (2020). “Characterization of Mortality by Covid-19 in a Health System in Central Mexico”. EC Pulmonology and Respiratory Medicine 9.12 (2020): 20-22
P-Y. Boëlle, T. Delory, X. Maynadier et al, (2020). Trajectories of Hospitalization in COVID-19 Patients: An Observational Study in France. J. Clin. Med.2020,9, 3148; doi:10.3390/jcm9103148www.mdpi.com/journal/jcm
Renato Seligman and Beatriz Graeff Santos Seligman (2020). “Pandemic in the 21st Century. The Challenge of COVID-19”. EC Pulmonology and Respiratory Medicine 9.8 (2020): 30-31.
Grasselli G et al. (2020). Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020 Apr 6; [e-pub]. (https://doi.org/10.1001/jama.2020.5394)
S. Richardson, J. S. Hirsch, M. Narasimhan at al. (2020). Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. Published online April 22, 2020. doi:10.1001/jama.2020.6775
Revised WHO classification and treatment of childhood pneumonia at health facilities. Geneva: World Health Organization, 2014. https://apps.who.int/iris/bitstream/handle/10665/137319/9789241507813_eng.pdf
F. Jehan, I. Nisar, S. Kerai et al. (2020). Randomized Trial of Amoxicillin for Pneumonia in Pakistan.July 2, 2020. N Engl J Med 2020; 383:24-34 DOI: 10.1056/NEJMoa1911998
A. B. Chang, K. Grimwood (2020). Antibiotics for Childhood Pneumonia — Do We Really Know How Long to Treat? July 2, 2020, N Engl J Med 2020; 383:77-79 DOI: 10.1056/NEJMe2016328
A-S. Ginsburg, T. Mvalo, E. Nkwopara et al. (2020). Amoxicillin for 3 or 5 Days for Chest-Indrawing Pneumonia in Malawian Children. N Engl J Med 2020; 383:13-23. DOI: 10.1056/NE
Igor Klepikov (2020). "Acute pneumonia. New doctrine and first treatment results." LAP-Lambert Academic Publishing. 2020. ISBN-10:6202679174; ISBN-13: 9786202679176
Lai J, Ma S, Wang Y, et al.(2020). Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019. JAMA Netw Open 2020;3(3):e203976-e203976.
R. E. Leiter (2020). Reentry. NEJM, October 14, 2020. DOI: 10.1056/NEJMp2027447
J. N. Rosenquist (2020). The Stress of Bayesian Medicine — Uncomfortable Uncertainty in the Face of Covid-19.NEJM, October 7, 2020. DOI: 10.1056/NEJMp2018857
Xu Chen. “Avoiding Defensive Medicine among Pandemic”. EC Emergency Medicine and Critical Care 4.12 (2020): 49-53.
Inflammation. https://en.wikipedia.org/wiki/Inflammation
Parakrama Chandrasoma; Clive R. Taylor (2005). "Part A. "General Pathology", Section II. "The Host Response to Injury", Chapter 3. "The Acute Inflammatory Response", sub-section "Cardinal Clinical Signs"". Concise Pathology (3rd ed.). McGraw-Hill. ISBN 978-0-8385-1499-3. OCLC 150148447. Retrieved 5 November 2008.
